Opendata, web and dolomites

LentiFactory

MAGIC (MAnufacturing of Gene delivery tools for Industrial and Clinical applications)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LentiFactory project word cloud

Explore the words cloud of the LentiFactory project. It provides you a very rough idea of what is the project "LentiFactory" about.

thanks    severe    immunotherapy    transform    cell    trials    company    lf    purity    intellectual    parallel    lack    ing    synthetic    world    customers    lentiviral    combine    lv    collaborative    highest    provider    patented    vector    patients    biology    grade    lentiflash    genetic    editing    carriers    diseases    biotech    cells    founded    deep    platforms    technological    capacity    powerful    requiring    expertise    class    car    market    tools    rna    thereby    edge    regulatory    vectors    committed    untreated    integrating    stem    accelerating    develops    primary    manufacturing    technologies    gene    rare    2005    proprietary    quality    infrastructure    extensive    therapy    gmp    move    cancers    industrial    stage    game    strategies    bioprocessing    therapeutic    vectalys    platform    transient    broad    changing    clinical    clear    engineering    cutting    generation    expression    stable    mainly    lives    property    producing   

Project "LentiFactory" data sheet

The following table provides information about the project.

Coordinator
FLASH THERAPEUTICS 

Organization address
address: CANAL BIOTECH II - 3 RUE DES SATELLITES
city: TOULOUSE
postcode: 31400
website: www.vectalys.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.vectalys.com/news/news-details/28-03-2017/lentifactory-horizon-2020-sme-instrument-phase-i-414
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FLASH THERAPEUTICS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Founded in 2005, Vectalys is a biotech company that develops world leading gene delivery technologies for industrial and therapeutic applications. Vectalys has built a state-of-the-art proprietary lentiviral vectors (LV) production platform to provide its customers and partners with the highest quality of LV. Based on 10 years of collaborative research, the resulting LV purity is now recognized as a key success factor for cutting-edge stable cell engineering on primary and stem cells. In parallel, thanks to its deep understanding of market needs, Vectalys has developed and patented a game-changing class of RNA carriers called LentiFlash (LF), a new generation of non-integrating LV dedicated to gene-editing applications requiring a transient expression.

Bioprocessing know-how, stable and transient delivery tools and intellectual property combine into a unique and powerful integrated platform capable of accelerating both gene-editing and immunotherapy applications. Based on recent results of early CAR-T cells clinical trials, mainly in the US, the market will now need an extensive scale-up capacity to produce GMP-grade LV and LF. The application potential is significant and includes both clinical approaches (gene therapy, gene-editing, and immunotherapy) and industrial systems (synthetic biology, modelling development).

Compared to the US, there is in Europe a clear lack of clinical manufacturing infrastructure and of integrated platforms that include both research and GMP production, thereby offering a broad expertise from vector design to therapeutic strategies. From a non-regulatory pre-clinical stage market, Vectalys has the capacity to move forward into the clinical stage market as a GMP grade value provider. The company has taken the technological lead in this field in Europe and is now committed to producing these tools at a clinical grade in order to transform the lives of patients with severe genetic and rare diseases as well as untreated cancers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LENTIFACTORY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LENTIFACTORY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More